State of New Jersey Common Pension Fund D Trims Stock Holdings in Pfizer Inc. $PFE

State of New Jersey Common Pension Fund D reduced its stake in Pfizer Inc. (NYSE:PFE) by 0.1% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,908,030 shares of the biopharmaceutical company’s stock after selling 2,274 shares during the period. State of New Jersey Common Pension Fund D’s holdings in Pfizer were worth $46,251,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Brighton Jones LLC grew its position in Pfizer by 1,282.4% in the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after acquiring an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC grew its position in Pfizer by 12.5% in the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after acquiring an additional 2,087 shares in the last quarter. GAMMA Investing LLC grew its position in Pfizer by 69.0% in the 1st quarter. GAMMA Investing LLC now owns 63,131 shares of the biopharmaceutical company’s stock valued at $1,600,000 after acquiring an additional 25,785 shares in the last quarter. Bessemer Group Inc. grew its position in Pfizer by 11.1% in the 1st quarter. Bessemer Group Inc. now owns 132,478 shares of the biopharmaceutical company’s stock valued at $3,358,000 after acquiring an additional 13,228 shares in the last quarter. Finally, Perigon Wealth Management LLC grew its position in Pfizer by 5.2% in the 1st quarter. Perigon Wealth Management LLC now owns 118,361 shares of the biopharmaceutical company’s stock valued at $2,999,000 after acquiring an additional 5,857 shares in the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Stock Performance

Shares of PFE opened at $24.79 on Friday. The stock has a 50 day moving average price of $24.87 and a 200 day moving average price of $24.17. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The company has a market capitalization of $140.92 billion, a price-to-earnings ratio of 13.18, a price-to-earnings-growth ratio of 0.82 and a beta of 0.55. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $29.17.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company had revenue of $14.65 billion during the quarter, compared to analysts’ expectations of $13.43 billion. During the same quarter in the previous year, the business earned $0.60 earnings per share. The firm’s revenue for the quarter was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Research analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.9%. The ex-dividend date is Friday, November 7th. Pfizer’s dividend payout ratio is 91.49%.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a research report on Wednesday, October 8th. UBS Group reaffirmed a “neutral” rating and issued a $28.00 target price on shares of Pfizer in a research report on Wednesday, October 1st. Citigroup boosted their price objective on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Bank of America boosted their price objective on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research report on Friday, October 3rd. Finally, Morgan Stanley lowered their price objective on Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a research report on Friday, October 10th. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $28.13.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.